Format

Send to

Choose Destination
J Infect. 2007 Jun;54(6):567-71. Epub 2006 Dec 26.

Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.

Author information

1
Division of Geographic Medicine and Infectious Diseases, Box 041, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA. dpoutsiaka@tufts-nemc.org <dpoutsiaka@tufts-nemc.org>

Abstract

OBJECTIVE:

Vancomycin resistant enterococcal (VRE) blood stream infection (BSI) in neutropenic patients is associated with poor outcome. We report our experience in treating VRE BSI in febrile, neutropenic patients with daptomycin, a recently licensed lipopeptide with bactericidal activity against VRE.

PATIENTS AND METHODS:

Patients with fever, neutropenia and VRE BSI were treated with more than one dose of daptomycin (either 6 mg/kg/day or 4 mg/kg/day) in an open label, emergency-use trial. Patients were then assessed for clinical and microbiological cures and survival. MIC's of isolates to daptomycin were determined.

RESULTS:

Nine febrile, neutropenic patients with VRE BSI received daptomycin. Four of 9 courses (44%) had clinical and/or microbiologic cure. Two of the 5 who failed cure died within 3 days of initiation of daptomycin. Five subjects survived to 30 days after the onset of BSI.

CONCLUSIONS:

Use of daptomycin in neutropenic patients with VRE BSI deserves further study as a treatment for VRE BSI in neutropenic patients.

PMID:
17188750
PMCID:
PMC1945103
DOI:
10.1016/j.jinf.2006.11.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center